Related Experiment Video
Updated: Feb 15, 2026
09:48
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
814
Camptothecin-based nanodrug delivery systems
Yan Wen1,2, Yingze Wang1, Xiaoli Liu1
1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China.
Cancer Biology & Medicine
|January 27, 2018
Summary
Camptothecin shows antitumor effects but faces challenges like toxicity and poor delivery. Nanotechnology offers a promising solution for developing improved camptothecin nanodrugs for cancer therapy.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Camptothecin exhibits broad-spectrum antitumor activity against various cancers.
- Camptothecin derivatives are crucial chemotherapeutic agents that inhibit topoisomerase 1 (Topo 1).
- Conventional camptothecin drugs suffer from systemic toxicity, low tumor accumulation, poor bioavailability, and limited water solubility.
Purpose of the Study:
- To review current advancements in camptothecin-based nanodrugs for cancer treatment.
- To highlight nanotechnology as a strategy to overcome limitations of traditional camptothecin formulations.
- To discuss potential applications of novel nanodrug delivery systems in clinical cancer therapy.
Main Methods:
- Literature review of camptothecin-based nanodrugs.
- Analysis of nanotechnology applications in overcoming drug delivery challenges.
- Summary of current research hotspots in nanopharmaceutical preparations for cancer therapy.
Main Results:
- Nanotechnology-based approaches are emerging as key strategies to enhance drug development.
- Various camptothecin-based nanodrugs have been developed to improve therapeutic efficacy.
- Nanodrug formulations show potential for increased drug accumulation at tumor sites and reduced systemic toxicity.
Conclusions:
- Nanotechnology offers significant potential for developing improved camptothecin delivery systems.
- Efficient nanodrug design can mitigate the limitations of conventional camptothecin chemotherapy.
- Further research into nanopharmaceutical preparations could lead to more effective clinical cancer therapies.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
21
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
21
01:23Ophthalmic Drug Delivery Systems
21
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
21
01:21Intrauterine Drug Delivery Systems
17
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
17
01:27Drug Delivery Systems: Different Types
16
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
16
01:26Oral Drug Delivery Systems: Continuous-Release Systems
20
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
20
01:11Oral Drug Delivery Systems: Delayed-Release Systems
23
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
23